0.20
-0.009(-4.29%)
Currency In USD
| Previous Close | 0.21 |
| Open | 0.22 |
| Day High | 0.23 |
| Day Low | 0.19 |
| 52-Week High | 0.77 |
| 52-Week Low | 0.1 |
| Volume | 1.23M |
| Average Volume | 9.86M |
| Market Cap | 83.27M |
| PE | -0.53 |
| EPS | -0.38 |
| Moving Average 50 Days | 0.22 |
| Moving Average 200 Days | 0.42 |
| Change | -0.01 |
Sangamo Therapeutics Advances Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease
GlobeNewswire Inc.
Mar 09, 2026 12:05 PM GMT
Data support potential of isaralgagene civaparvovec as a one-time, well tolerated and durable Fabry disease gene therapy to provide meaningful, multi-organ clinical benefits that could fundamentally shift Fabry treatment paradigm STAAR study demonstr
Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at WORLDSymposium™ 2026
GlobeNewswire Inc.
Feb 03, 2026 9:05 PM GMT
Data support potential of isaralgagene civaparvovec as a one-time, well tolerated and durable Fabry disease gene therapy to provide meaningful, multi-organ clinical benefits that could fundamentally shift Fabry treatment paradigm STAAR study demonstr
Sangamo Therapeutics Announces Pricing of $25.0 Million Underwritten Offering
GlobeNewswire Inc.
Feb 03, 2026 2:10 PM GMT
RICHMOND, Calif., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the pricing of an underwritten offering consisting of 35,190,292 shares of its common stock and pre-funded wa